For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of this treatment and the formulated version represents a genuine change. These innovative therapies protect the transthyretin protein, slowing its harmful build-up and lessening the impac